Form 4: MBX Biosciences Insider Trades Shares Following IPO

Anthony A. Florence Jr., a director and 10% owner of MBX Biosciences, reports transactions involving common stock and convertible preferred stock on September 16, 2024, following the company's IPO.

Summary

• On September 16, 2024, Anthony A. Florence Jr., a director and 10% owner of MBX Biosciences, executed several transactions.
• These transactions involved the conversion of Series A and Series B Convertible Preferred Stock into common stock immediately prior to the company's IPO.
• Specifically, 12,299,854 shares of Series A Convertible Preferred Stock were converted into 1,023,103 shares of common stock.
• Additionally, 25,142,840 shares of Series B Convertible Preferred Stock were converted into 2,091,383 shares of common stock.
• Florence also purchased 500,000 shares of common stock at a price of $16 per share.
• Following these transactions, the total amount of common stock beneficially owned indirectly by Florence is 3,614,486 shares.
• Florence disclaims beneficial ownership of the securities held by NEA 17, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider transactions, which are expected after an IPO. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure following MBX Biosciences' IPO, providing transparency into insider transactions as the company enters the public market. Insider transactions are closely watched by investors for signals about management's confidence in the company's future prospects.

Stakeholder Impact

• Shareholders are informed about insider transactions, providing transparency.
• The transactions may influence investor perception of the company's stock.

Key Dates